Limits...
Japanese experience with milnacipran, the first serotonin and norepinephrine reuptake inhibitor in Japan.

Higuchi T, Briley M - Neuropsychiatr Dis Treat (2007)

Bottom Line: As such it has attracted relative little interest from clinician investigators as a research tool.Japan, however, represents a unique situation because in 1999 milnacipran was launched within months of the first SSRI and is still the only SNRI in Japan together with only two SSRIs (a third has just been introduced).This article reviews these Japanese studies with milnacipran.

View Article: PubMed Central - PubMed

Affiliation: Musashi Hospital, National Centre for Neurology and Psychiatry, Tokyo, Japan.

ABSTRACT
Milnacipran is a serotonin and norepinephrine reuptake inhibitor (SNRI), with a balanced potency for the inhibition of the reuptake of the two monoamines. In this, it contrasts with venlafaxine and duloxetine which, while possessing a dual action, have a selectivity of the order of 30-fold and 10-fold respectively for the reuptake of serotonin. Milnacipran has mainly been launched in countries where the selective serotonin reuptake inhibitors (SSRIs) and venlafaxine had been established for several years. As such it has attracted relative little interest from clinician investigators as a research tool. Japan, however, represents a unique situation because in 1999 milnacipran was launched within months of the first SSRI and is still the only SNRI in Japan together with only two SSRIs (a third has just been introduced). This has led to a large number of investigative clinical studies, many of which give interesting insights into the potential of milnacipran in the treatment of depression and of other disorders. This article reviews these Japanese studies with milnacipran.

No MeSH data available.


Related in: MedlinePlus

Response to milnacipran at different doses. 66 patients were randomized and titrated to a daily dose of milnacipran of either 75 mg or 150 mg over 2–3 weeks; This dose was then maintained stable for 8 weeks; 25 and 26 patients, respectively, completed the study in the 75 mg/d and 150 mg/d groups; Response = reduction ≥50% in HAMD17 from baseline; Remission = HAMD17 <7; Drawn from data from Kanemoto et al (2004).
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2654524&req=5

f2-ndt-3-41: Response to milnacipran at different doses. 66 patients were randomized and titrated to a daily dose of milnacipran of either 75 mg or 150 mg over 2–3 weeks; This dose was then maintained stable for 8 weeks; 25 and 26 patients, respectively, completed the study in the 75 mg/d and 150 mg/d groups; Response = reduction ≥50% in HAMD17 from baseline; Remission = HAMD17 <7; Drawn from data from Kanemoto et al (2004).

Mentions: Two different doses of milnacipran (75 mg/d and 150 mg/d) were compared in 66 outpatients with major depression who were experiencing their first depressive episode or whose previous depressive episode had occurred at least 1 year earlier (Kanemoto et al 2004). Patients were randomized and titrated to a daily dose of milnacipran of either 75 mg or 150 mg over 2–3 weeks. This dose was then maintained stable for 8 weeks. At the end of the study the rates of both response (≥50% decrease in HAMD17 from baseline) and remission (HAMD17 < 7) were significantly greater in patients receiving milnacipran at 150 mg/d compared with patients receiving milnacipran at 75 mg/d (Figure 2). There was no significant difference in the incidence of adverse events.


Japanese experience with milnacipran, the first serotonin and norepinephrine reuptake inhibitor in Japan.

Higuchi T, Briley M - Neuropsychiatr Dis Treat (2007)

Response to milnacipran at different doses. 66 patients were randomized and titrated to a daily dose of milnacipran of either 75 mg or 150 mg over 2–3 weeks; This dose was then maintained stable for 8 weeks; 25 and 26 patients, respectively, completed the study in the 75 mg/d and 150 mg/d groups; Response = reduction ≥50% in HAMD17 from baseline; Remission = HAMD17 <7; Drawn from data from Kanemoto et al (2004).
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2654524&req=5

f2-ndt-3-41: Response to milnacipran at different doses. 66 patients were randomized and titrated to a daily dose of milnacipran of either 75 mg or 150 mg over 2–3 weeks; This dose was then maintained stable for 8 weeks; 25 and 26 patients, respectively, completed the study in the 75 mg/d and 150 mg/d groups; Response = reduction ≥50% in HAMD17 from baseline; Remission = HAMD17 <7; Drawn from data from Kanemoto et al (2004).
Mentions: Two different doses of milnacipran (75 mg/d and 150 mg/d) were compared in 66 outpatients with major depression who were experiencing their first depressive episode or whose previous depressive episode had occurred at least 1 year earlier (Kanemoto et al 2004). Patients were randomized and titrated to a daily dose of milnacipran of either 75 mg or 150 mg over 2–3 weeks. This dose was then maintained stable for 8 weeks. At the end of the study the rates of both response (≥50% decrease in HAMD17 from baseline) and remission (HAMD17 < 7) were significantly greater in patients receiving milnacipran at 150 mg/d compared with patients receiving milnacipran at 75 mg/d (Figure 2). There was no significant difference in the incidence of adverse events.

Bottom Line: As such it has attracted relative little interest from clinician investigators as a research tool.Japan, however, represents a unique situation because in 1999 milnacipran was launched within months of the first SSRI and is still the only SNRI in Japan together with only two SSRIs (a third has just been introduced).This article reviews these Japanese studies with milnacipran.

View Article: PubMed Central - PubMed

Affiliation: Musashi Hospital, National Centre for Neurology and Psychiatry, Tokyo, Japan.

ABSTRACT
Milnacipran is a serotonin and norepinephrine reuptake inhibitor (SNRI), with a balanced potency for the inhibition of the reuptake of the two monoamines. In this, it contrasts with venlafaxine and duloxetine which, while possessing a dual action, have a selectivity of the order of 30-fold and 10-fold respectively for the reuptake of serotonin. Milnacipran has mainly been launched in countries where the selective serotonin reuptake inhibitors (SSRIs) and venlafaxine had been established for several years. As such it has attracted relative little interest from clinician investigators as a research tool. Japan, however, represents a unique situation because in 1999 milnacipran was launched within months of the first SSRI and is still the only SNRI in Japan together with only two SSRIs (a third has just been introduced). This has led to a large number of investigative clinical studies, many of which give interesting insights into the potential of milnacipran in the treatment of depression and of other disorders. This article reviews these Japanese studies with milnacipran.

No MeSH data available.


Related in: MedlinePlus